Cvs Fast Acting Baby Teething

Description

The drug is formulated as a tablet containing the active ingredient insert active ingredient name here. The tablet exhibits insert physical characteristics, e.g., color, shape, size. Inactive ingredients include list of inactive ingredients.

Uses and Indications

This drug is indicated for the temporary relief of sore gums associated with teething in infants and children aged 4 months and older.

Limitations of Use: This product is intended for use in the specified age group and should not be administered to children younger than 4 months.

Dosage and Administration

Healthcare professionals are advised to follow the steps outlined below for the proper dosage and administration of the product.

Prior to application, it is essential to wash hands thoroughly to ensure cleanliness and prevent contamination. The tip of the tube should be cut open at the designated score mark to facilitate the dispensing of the product.

A small, pea-sized amount of the product should be applied to the affected area using either a fingertip or a cotton swab. This application may be performed up to four times daily, or as directed by a dentist or doctor, depending on the specific needs of the patient.

For infants under 4 months of age, it is imperative to consult with a dentist or doctor before administering the product to ensure safety and appropriateness of use.

Contraindications

Use is contraindicated in children due to the risk of accidental ingestion. In the event of an overdose or allergic reaction, immediate medical attention should be sought, or a Poison Control Center should be contacted.

Warnings and Precautions

The use of this product is contraindicated in infants with a known allergy to local anesthetics, including butacaine, benzocaine, procaine, or any other "caine" anesthetics. Healthcare professionals should ensure that patients do not exceed the recommended dosage or duration of use, which is limited to a maximum of 7 days unless otherwise directed by a dentist or physician.

It is important to note that fever and nasal congestion are not typical symptoms of teething and may suggest an underlying infection. Should these symptoms persist, it is advised to contact a dentist or physician for further evaluation.

Patients should be instructed to discontinue use and seek medical advice if sore mouth symptoms do not improve within 7 days. Additionally, if any irritation, pain, or redness persists, or if swelling, rash, or fever develops, immediate consultation with a healthcare provider is warranted.

In the event of an overdose or suspected allergic reaction, patients must seek emergency medical assistance or contact a Poison Control Center without delay. Monitoring for these adverse effects is crucial to ensure patient safety and effective management of any complications that may arise.

Side Effects

Patients should be aware of the potential adverse reactions associated with this product. A significant warning includes an allergy alert; the product should not be used in patients with a history of allergy to local anesthetics such as butacaine, benzocaine, procaine, or other "caine" anesthetics.

In clinical practice, patients are advised to stop using the product and consult a dentist or doctor if any of the following occur: sore mouth symptoms that do not improve within 7 days, persistent irritation, pain, or redness, or the development of swelling, rash, or fever.

In the event of an overdose or an allergic reaction, it is crucial for patients to seek medical attention immediately or contact a Poison Control Center. These precautions are essential to ensure patient safety and effective management of any adverse reactions.

Drug Interactions

The use of this product is contraindicated in patients with a known history of allergy to local anesthetics, including but not limited to butacaine, benzocaine, procaine, or other "caine" anesthetics. Clinicians should exercise caution and ensure that patients are screened for any previous allergic reactions to these agents prior to administration.

Packaging & NDC

Below are the non-prescription pack sizes of Cvs Fast Acting Baby Teething (benzocaine). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 4 months and older may use this product for the temporary relief of sore gums due to teething. For infants under 4 months of age, consultation with a dentist or doctor is advised prior to use.

Healthcare professionals should be aware of an allergy alert: this product should not be used in patients with a history of allergy to local anesthetics, including butacaine, benzocaine, procaine, or other "caine" anesthetics.

Dosage should not exceed the recommended amount or duration of 7 days unless directed by a dentist or doctor. It is important to note that fever and nasal congestion are not typical symptoms of teething and may indicate an underlying infection; if these symptoms persist, a healthcare provider should be contacted.

Patients should discontinue use and seek medical advice if sore mouth symptoms do not improve within 7 days, if irritation, pain, or redness persists, or if swelling, rash, or fever develops.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Safety during pregnancy has not been established for this medication. Pregnant patients or those planning to become pregnant should not use this medication without first consulting a healthcare provider. The potential risks to the fetus are not well studied, and caution is advised when considering the use of this medication in pregnant individuals.

Healthcare providers should be consulted regarding any necessary dosage modifications if the patient is pregnant. It is recommended that this medication be used only if clearly needed, and when the benefits outweigh the risks during pregnancy.

Lactation

Lactating mothers should consult a healthcare professional before using this product. There is a potential for excretion in breast milk, and the effects on nursing infants are not well studied; therefore, caution is advised.

Renal Impairment

Patients with renal impairment may not have specific information regarding dosage adjustments, special monitoring, or safety considerations outlined in the prescribing information. Therefore, healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment and individualized patient assessment. Regular monitoring of renal function is advisable to ensure patient safety and therapeutic efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdose or an allergic reaction, it is imperative to seek immediate medical attention. Healthcare professionals are advised to contact a Poison Control Center without delay to ensure appropriate management of the situation.

Symptoms of overdose may vary depending on the specific substance involved; therefore, a thorough assessment of the patient's condition is essential. Prompt recognition of symptoms can facilitate timely intervention and improve patient outcomes.

Management procedures should be initiated as soon as an overdose is suspected. This may include supportive care, monitoring of vital signs, and symptomatic treatment as necessary. The involvement of poison control experts can provide additional guidance on specific antidotes or interventions that may be required based on the substance involved in the overdose.

It is crucial for healthcare providers to remain vigilant and act swiftly in cases of overdose to mitigate potential complications and ensure patient safety.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. It is important for patients to understand the potential risks associated with overdose or allergic reactions. In such cases, they should be instructed to seek medical attention immediately or contact a Poison Control Center for guidance. This information is crucial for ensuring patient safety and promoting responsible use of the medication.

Storage and Handling

The product is supplied in a tube format. It should be stored at room temperature to maintain its efficacy. Healthcare professionals are advised to inspect the tube prior to use; the product must not be used if the tube tip is cut before opening, as this may compromise the integrity of the product.

Additional Clinical Information

The product is administered orally and should be applied to the affected area up to four times daily, or as directed by a dentist or doctor. Clinicians should counsel patients on the following important points: the product should not be used if the patient has a history of allergy to local anesthetics such as butacaine, benzocaine, procaine, or other "caine" anesthetics. Patients are advised not to exceed the recommended dosage or use the product for more than 7 days unless directed by a healthcare professional.

Additionally, clinicians should inform patients that fever and nasal congestion are not typical symptoms of teething and may indicate an underlying infection; persistent symptoms should prompt a consultation with a dentist or doctor. Patients should discontinue use and seek medical advice if sore mouth symptoms do not improve within 7 days, or if they experience irritation, pain, redness, swelling, rash, or fever.

Drug Information (PDF)

This file contains official product information for Cvs Fast Acting Baby Teething, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)